Volume 149, Issue 3, Pages (June 2018)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,

Volume 141, Issue 2, Pages (May 2016)

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

From: Inefficiencies and High-Value Improvements in U. S

Copyright © 2015 by the American Osteopathic Association.

Markers of human papillomavirus infection and their correlation with cervical dysplasia in human immunodeficiency virus-positive women E. Riva, D. Serraino,

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

QUIZ QUESTIONS 1) WHAT ARE THE TWO TYPES OF CERVICAL CANCER?

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Clinical significance of signal pattern of high-risk human papillomavirus using a novel fluorescence in situ hybridization assay in cervical cytology

Volume 69, Issue 1, Pages (January 2016)

Volume 150, Issue 1, Pages (July 2018)

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Volume 151, Issue 1, Pages (October 2018)

Volume 5, Issue 1, Pages e45-e58 (January 2018)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 144, Issue 2, Pages (February 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 135, Issue 1, Pages (October 2014)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 136, Issue 2, Pages (February 2015)

Kavitha K. Reddy Journal of Investigative Dermatology

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

HPV vaccines – A review of the first decade

Volume 147, Issue 1, Pages (October 2017)

Cervical excisional treatment of young women: A population-based study

Volume 121, Issue 1, Pages (April 2011)

SH-sheikhhasani Gyn-oncologist

Volume 130, Issue 3, Pages (September 2013)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis Chunqing Lin,

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 130, Issue 1, Pages (July 2013)

Volume 153, Issue 1, Pages (April 2019)

Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after.

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled.

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 2, Issue 6, Pages (June 2017)

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.

Volume 154, Issue 2, Pages (August 2019)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 149, Issue 3, Pages 498-505 (June 2018) The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results Mark H. Stoler, Thomas C. Wright, Valentin Parvu, Laurence Vaughan, Karen Yanson, Karen Eckert, Tobi Karchmer, Salma Kodsi, Charles K. Cooper Gynecologic Oncology Volume 149, Issue 3, Pages 498-505 (June 2018) DOI: 10.1016/j.ygyno.2018.04.007 Copyright © 2018 The Authors Terms and Conditions

Gynecologic Oncology 2018 149, 498-505DOI: (10.1016/j.ygyno.2018.04.007) Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Subject reconciliation during baseline enrollment and participation in this trial. Abbreviations: ≥ASC-US, atypical squamous cells of undetermined significance or greater; CIN, cervical intraepithelial neoplasia; hrHPV, high-risk human papillomavirus; NILM, negative for intraepithelial lesions or malignancies; neg, negative; p16, p16INK4A protein; PI, principal investigator; pos, positive; UNSAT, unsatisfactory cytology. Gynecologic Oncology 2018 149, 498-505DOI: (10.1016/j.ygyno.2018.04.007) Copyright © 2018 The Authors Terms and Conditions